Dr Fiona Miall

Deputy Head of Medical School, Director of Clinical Studies & Honorary Consultant Haematologist

School/Department: Leicester Medical School



I graduated from Nottingham University Medical School in 1994 and early in my training recognised that Haematology was the specialty for me. So having spent some time abroad and passed MRCP I came to Leicester for a 6 month stand-alone post in 1998 with a plan to apply for specialist training in the North yet I stayed and achieved FRCPath largely due to the hugely supportive friendly training environment and the breadth and depth of Haematological presentations seen here.

I have been a Consultant Haematologist since 2006 sub-specialising in lymphoma but with all-round on-call practice. I enjoy the clinical role and also my clinical trials work. I have had an undergraduate role from the start of my consultant career firstly co-designing and running the cancer care block and then shaping the year 5 Foundation Assistantships within the new Leicester Medical School curriculum before taking on Head of Year 5.

From April 2019 to Summer 2022 I was Director of Clinical Studies overseeing phase 2 (years 3, 4 & 5) of the curriculum and the team who delivers this, including embracing the challenges brought by the COVID pandemic on clinical education. Since March 2022 I have been working as one of the two Deputy Heads of School for the School of Medicine and I continue to practice as a hospital consultant.



For many years the Leicester lymphoma / CLL research team led by Professor Martin Dyer has had clinical trials running across a Phase 1-3 portfolio with an interest in targeted therapy and strength in reverse translational studies. I have had the privilege to locally lead many NCRI and commercial studies and to recruit patients to studies across the wider portfolio looking at diagnostic work up and treatment. I am a member of the NCRI Hodgkin lymphoma study group. I sit on the Trial Management Group for clinical studies.


(0) Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Herrera AF, Burton C, Radford J, Miall F, Townsend W, Santoro A, Zinzani PL, Lewis D, Fowst C, Brar S, Huang B, Thall A, Collins GP.
Blood Adv. 2021 Sep 14;5(17):3387-3396. doi: 10.1182/bloodadvances.

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A, Pirrie SJ, Linton K, Warbey V, Paterson K, Davies AJ, Collins GP, Menne T, McKay P, Fields PA, Miall FM, Nagy E, Wheatley K, Reed R, Baricevic-Jones I, Barrington S, Radford J.
Br J Haematol. 2021 Apr;193(1):63-71. doi: 10.1111/bjh.17073.

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J, Mula Kh A, Shah N, Cheung CK, Timmins MA, Creasey T, Linton K, Smith J, Fox CP, Miall F, Cwynarski K, McKay P.
Blood Adv. 2020 Aug 11;4(15):3586-3593. doi: 10.1182/bloodadvances.

The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL.
Allchin RL, Wickenden K, Pilgrim S, Wilson-Morkeh I, Miall FM.
Hemasphere. 2020 Nov 24;4(6):e501. doi: 10.1097/HS9.0000000000000501. 

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
Martì≠nez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP.
Br J Haematol. 2019 Mar;184(6):957-968. doi: 10.1111/bjh.15722.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA, Phillips EH, Linton KM, Arumainathan A, Kassam S, Gibb A, Allibone S, Radford J, Peggs K, Burton C, Stewart G, LeDieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP.
Br J Haematol. 2017 Nov;179(3):471-479. doi: 10.1111/bjh.14898. 

Enteropathy-associated T-cell lymphoma presenting as cutaneous deposits.
Webster A, Crea P, Bamford MW, Hew R, Griffin Y, Miall F.
Br J Haematol. 2017 Jan;176(1):7. doi: 10.1111/bjh.14375. 

Use of 18F-fludeoxyglucose positron emission tomography-CT in the management of breast implant-associated anaplastic large cell lymphoma.
Ladani S, Valassiadou K, Griffin Y, Miall F.
BJR Case Rep. 2016 Jul 28;2(3):20150424. doi: 10.1259/bjrcr.20150424.

A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome.
Sanders L, Jayne S, Kennedy B, Miall F, Aukema SM, Siebert R, Wagner SD, Dyer MJ.
Case Rep Hematol. 2014;2014:120714. doi: 10.1155/2014/120714.

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC.
Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0.


I oversee all phase 2 (years 3, 4 & 5) teaching within the Leicester Medical School Curriculum as Director of Clinical Studies and also teach Haematology across the 5 years of the course.

Press and media

Medical Education; Graduating doctors.


Back to top